Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotrimazole + metronidazole is a fixed-dose combination of two small molecule drugs used primarily for the treatment of vaginal infections, especially mixed infections involving both fungi and anaerobic bacteria. Clotrimazole is an imidazole antifungal agent that inhibits the synthesis of ergosterol, a key component of fungal cell membranes, thereby stopping fungal growth. Metronidazole is a nitroimidazole antibiotic and antiprotozoal agent that works by entering microbial cells and generating free radicals which damage DNA, leading to cell death. This combination targets both fungal pathogens (such as Candida species) and anaerobic bacteria commonly implicated in vaginitis[5]. It is typically administered intravaginally as tablets or gel.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole + metronidazole.